Progrès dans la prévention du cancer

Abstrait

Evaluation of Docetaxel vs. Tamoxifen in Combined Therapies Based on Overall Survival Rate (OSR) Endpoint among Female Breast Cancer Patients

Oluwafemi Olawuyi and Melanie Tidman

In this review, overall survival rate (OSR) result and safety data were evaluated based on data from four clinical trials on combined therapies of Docetaxel and Tamoxifen among breast cancer patients, which were published in peer-reviewed journals. Data was extracted from single treatment trials of Docetaxel plus Cisplatin, and Tamoxifen plus Vorinostat, and randomized trials of Docetaxel plus Capecitabine, and Tamoxifen plus Buserelin. Docetaxel was found to have slightly longer OSR than Tamoxifen in combined therapies, and it has better individual strength in combined therapies based on OSR comparison in the trials’ treatment arms. However, a considerable number of toxicities caused by combined therapies of both drugs negates the superiority of the efficacy of combined therapies of one of the drugs over the other. Although other combined cancer drugs boost efficacy of Docetaxel and Tamoxifen in the combined therapies, they should be selected to minimize the toxicities in combined therapies of both drugs.